Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.
If you were prescribed this medicine, other products containing Trifluoperazine hydrochloride may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.
for
Trifluoperazine 5mg/5ml Oral solution contains the active ingredient trifluoperazine present as hydrochloride, which belongs to a class of drugs called phenothiazine tranquilisers, also referred to as a neuroleptic drug. It influences the activity of certain brain cells by decreasing the effect of dopamine, a natural chemical in the brain.
e Trifluoperazine Oral Solution
Do not take Trifluoperazine Oral Solution:
This medicine will not be given to patients who are in a coma. Warnings and precautions Talk to your doctor or pharmacist before taking Trifluoperazine Oral Solution if you are:
Trifluoperazine 5mg/5ml Oral Solution contains sodium, ethanol, sodium benzoate, propylene glycol and benzyl alcohol. This medicine contains less than 1 mmol sodium (23 mg) per ml, that is to say essentially 'sodium-free'. This medicinal product contains small amounts of ethanol (alcohol), less than 100 mg per 25 ml. This medicine contains 1 mg sodium benzoate in each ml. This medicine contains 100.95 mg propylene glycol in each ml. If your child is less than 5 years old, talk to your doctor or pharmacist before giving them this medicine, in particular if they use other medicines that contain propylene glycol or alcohol. If you are pregnant or breast‐feeding, do not take this medicine unless recommended by your doctor. Your doctor may carry out extra checks while you are taking this medicine. If you suffer from a liver or kidney disease, do not take this medicine unless recommended by your doctor. Your doctor may carry out extra checks while you are taking this medicine. This medicine contains 0.0257 mg benzyl alcohol in each ml. Benzyl alcohol may cause allergic reactions. Ask your doctor or pharmacist for advice if you are pregnant or breast‐feeding or if you have a liver or kidney disease. This is because large amounts of benzyl alcohol can build-up in your body and may cause side effects (called "metabolic acidosis"). 3.
Trifluoperazine Oral Solution
Always take this medicine exactly as your doctor or pharmacist has told you. The pharmacist's label on your pack will tell you how much and how often you should take your oral solution. Please read the label carefully. You should check with your doctor or pharmacist if you are not sure. Do not take more than your doctor has recommended. Your doctor will decide on a suitable dose depending on your condition. The usual dose is shown in the table below. You will usually need to take your medicine twice or three times a day, depending on the dose your doctor has chosen for you. The recommended dose is: Remember each 5ml of oral solution contains 5mg of "Trifluoperazine" Patient Type
Low dosage For the treatment of anxiety or nausea and vomiting
High dosage For the control of schizophrenia and related conditions
Adults
The usual dose is 2 mg to High dose in adults is 6mg a day 5-25mg a day in divided doses
Elderly The starting dose of oral The starting dose of (over 65 years of age) solution should be no oral solution should be more than half that of no more than half that adult patients of adult patients Children For children aged 3-5 High dose in children years, the dose is no more (aged 6-12 years) is than 1mg a day. For 5mg in divided doses. children aged 6-12 years the dose is no more than 4mg a day.
During treatment your doctor should regularly check you for physical side effects, changes in your blood counts or liver function, and any heart problem, especially if you taking this medicine for a long time or are also taking other medicines. Method of administration Oral use A graduated oral syringe, a Press-In bottle Adaptor and a graduated dosing cup are provided with the product. Instructions for using the oral syringe and the dosing cup Please read these instructions carefully before taking the medicine. This will help you to use the oral syringe and the dosing cup correctly. What you will be using
A press in bottle adapter: that you insert into the neck of the bottle (only if you are going to use the oral dosing syringe to measure your dose). once you have inserted it, do not remove it. A bottle containing the medicine: that has a child-resistant screw cap. always screw the cap back on after use. An oral dosing syringe: that consists of a clear plastic tube with a plunger inside. the oral syringe fits into the bottle adapter and is used to measure out the required amount of medicine from the bottle (for doses below 10ml). use a new bottle adapter and oral dosing syringe each time you start a new bottle of medicine. A dosing cup: That should be used if the prescribed dose is 10ml or more. If you are going to use the cup to measure your dose, do not insert the adapter into the neck of the bottle. Empty the required dose of medicine into the dosing cup and then check the total volume of solution. Drink the entire solution right away. To clean the cup: rinse the cup with clean water dry the cup with a clean tissue and place it back over the cap of the bottle. If you are going to use the oral dosing syringe to measure your dose: Fitting the press in bottle adapter into a new bottle of medicine 1. Remove the cap from the bottle by pushing it down firmly and turning it anticlockwise (as shown on the top of the cap). 2. Holding the open bottle upright on a table, push the bottle adapter firmly into the neck of the bottle as far as it will go. Note: You may not be able to push the bottle adapter down fully but this does not matter as it will be forced into the bottle when you screw the cap back on. 3. screw the cap back on the bottle. Preparing a dose of medicine 4. Remove the cap from the bottle by pushing it down firmly and turning it anticlockwise (as shown on the top of the cap). 5. Check that the plunger is pushed fully into the oral syringe.
6. Keeping the bottle upright, insert the oral syringe firmly into the bottle adapter.
7. Holding the oral syringe in place, carefully turn the bottle and oral syringe upside down. 8. Before you measure your dose you need to get rid of any large bubbles that may be trapped in the oral syringe. To do this:
12. Remove the oral syringe from the bottle adapter by gently twisting it out.
Taking the medicine 13. Sit upright. 14. Put the end of the oral syringe into the mouth. 15. Slowly push the plunger in and swallow the medicine directly from the oral syringe.
16. Replace the child-resistant screw cap after use. 17. To clean the oral syringe: Rinse the syringe by drawing water into the syringe and pushing the syringe plunger to the bottom of the syringe barrel, at least three times. Do this after each time that you use the oral syringe. If you take more Trifluoperazine Oral Solution than you should If you think that you, or any other person, have taken too much oral solution, contact your doctor or hospital casualty department immediately. Take this leaflet and any remaining oral solution with you so that the medical staff know exactly what you have taken. If you forget to take Trifluoperazine Oral Solution If you miss a dose, wait until your next dose. Do not take the dose you have missed. You can then carry on as before. Do not take more than one dose at a time. If you stop taking Trifluoperazine Oral Solution
Continue to take Trifluoperazine Oral Solution even if you no longer feel ill. Do not stop taking this medicine without talking with your doctor first, especially if you have taken large doses for a long time. When the time comes to stop your doctor will probably decrease your dose gradually as stopping the oral solution suddenly may cause ill-effects such as nausea (feeling sick), vomiting (being sick), sweating and difficulty in sleeping. For mood disorders and schizophrenia, it may take several weeks for you to feel the full benefit of this medicine. If you stop taking this medicine suddenly, your symptoms may come back. 4.
Like all medicines, this medicine can sometimes cause side effects, although not everybody gets them. If you notice any of these symptoms seek medical advice immediately. If you experience any below serious side effects, tell your doctor immediately:
Blood clots in the veins especially in the legs (symptoms include swelling, pain and redness in the leg), which may travel through blood vessels to the lungs causing chest pain and difficulty in breathing. Abnormal heart rhythms including a life-threatening irregular heart beat called torsades de pointes or abnormal ECG heart tracing or heart stopping (cardiac arrest) and unexplained death. Patients may develop Neuroleptic Malignant Syndrome. This causes a high temperature, rigid muscles, drowsiness, occasional loss of consciousness, and requires emergency admission to hospital for treatment. The following symptoms may occur in newborn babies, of mothers that have used Trifluoperazine in the last trimester (last three months of their pregnancy): shaking, muscle stiffness and/or weakness, sleepiness, agitation, breathing problems and difficulty in feeding. If your baby develops any of these symptoms you may need to contact your doctor.
Other side effects are: Rare: may affect up to 1 in 1,000 people
gentle movements of the neck, head or trunk. Uncontrollable movements of the arms and legs have also been reported in these patients.
Trifluoperazine Oral Solution
Keep this medicine out of the sight and reach of children. Do not use this medicine after the expiry date which is stated on the carton and bottle label after 'Exp'. The expiry date refers to the last day of that month. Once the bottle is opened use within 2 months. Keep bottle in the original carton to protect from light. Do not throw away medicines via waste water or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment. 6.
What Trifluoperazine Oral Solution contains The active substance in Trifluoperazine 5mg/5ml Oral Solution is trifluoperazine hydrochloride. Each 5ml of Oral solution contains 5mg trifluoperazine present as hydrochloride. The other ingredients are: sodium benzoate, propylene glycol, citric acid anhydrous, sodium citrate, sucralose, orange flavour (SP 14104/04) (including propylene glycol, ethanol, benzyl alcohol), natracol curcumin (E100) (including propylene glycol), citric acid and purified water. What Trifluoperazine Oral Solution looks like and contents of the pack Trifluoperazine Oral solution is a clear, yellow coloured solution with characteristic orange odour. It is available in an amber glass bottle containing 150 ml of medicine. This pack also contains a 5 ml plastic oral dosing syringe with 0.1 ml graduations, an adapter and 20 ml dosing cup. Marketing Authorisation Holder Focus Pharmaceuticals Limited, Dashwood House, 69 Old Broad Street, London, EC2M 1QS, United Kingdom
Manufacturers IASIS PHARMA HELLAS S.A 137, Filis Ave. 13451 Kamatero Athens, Greece RAFARM SA Thesi Pousi-Xatzi Agiou Louka, Paiania Attiki, 19002, PO Box 37, Greece The marketing authorisation holder will ensure that the package information leaflet is made available on request from patient's organisations in formats appropriate for the blind and partially-sighted. Contact Number: 44 (0) 8700 70 30 33 This leaflet was last revised in December 2023.
Trifluoperazine 5 mg/5 ml Oral Solution comes as oral solution containing 5mg / 5ml. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.
The active substance in Trifluoperazine 5 mg/5 ml Oral Solution is trifluoperazine hydrochloride.
Medicines with the same active substance, strength and form include: Trifluoperazine 5mg/5ml Oral Solution. They are interchangeable only if your prescriber or pharmacist says so.
This leaflet reproduces the patient information leaflet approved for Trifluoperazine 5 mg/5 ml Oral Solution, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.
Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.
The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.
Low dosage: Trifluoperazine oral solution is indicated as an adjunct in the short-term management of anxiety states, depressive symptoms secondary to anxiety and agitation. Orally it is also indicated in the symptomatic treatment of nausea and vomiting.
High dosage: Trifluoperazine oral solution is intended for the treatment of symptoms and prevention of relapse in schizophrenia and in other psychoses, especially of the paranoid type, but not in depressive psychoses. It may also be used as an adjunct in short-term management of severe psychomotor agitation and of dangerously impulsive behaviour in, for example, mental subnormality.
Posology
Adults
Low dosage: 2-4 mg a day given in divided doses, according to the severity of the patient's condition. If necessary, dosage may be increased to 6 mg a day, but above this level extrapyramidal symptoms are more likely to occur in some patients.
High dosage: The recommended starting dosage for physically fit adults is 5 mg twice a day after a week this may be increased to 15 mg a day. If necessary, further increases of 5 mg may be made at three-day intervals, but not more often. When satisfactory control has been achieved, dosage should be reduced gradually until an effective maintenance level has been established.
As with all major tranquillisers, clinical improvement may not be evident for several weeks after starting treatment, and there may be delay before recurrence of symptoms after stopping treatment. Gradual withdrawal from high dosage treatment is advisable.
Paediatric population
Low dosage: For children 3-5 years, up to 1 mg a day given in divided doses.
For children aged 6-12 years, the dosage may be increased to a maximum of 4 mg a day.
High dosage: For children aged 6-12 years, the initial oral dosage should not exceed 5 mg a day, given in divided doses. Any subsequent increase should be made with caution, at intervals of not less than three days, and taking into account age, body weight and severity of symptoms.
Elderly
Reduce starting dose in elderly or frail patients by at least half.
Method of administration
Oral use
A graduated oral syringe, a Press-In bottle Adaptor and a graduated dosing cup are provided with the product.
• Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
• Do not use Trifluoperazine oral solution in comatose patients, particularly if associated with other central nervous system depressants.
• Do not use Trifluoperazine oral solution in those with existing blood dyscrasias, or known liver damage.
• Patients with uncontrolled cardiac decompensation should not be given Trifluoperazine oral solution.
Trifluoperazine oral solution should be discontinued at the first sign of clinical symptoms of tardive dyskinesia and Neuroleptic Malignant Syndrome.
Patients on long-term phenothiazine therapy require regular and careful surveillance with particular attention to tardive dyskinesia and possible eye changes, blood dyscrasias, liver dysfunction and myocardial conduction defects, particularly if other concurrently administered drugs have potential effects in these systems.
Care should be taken when treating elderly patients, and initial dosage should be reduced. Such patients can be especially sensitive, particularly to extrapyramidal and hypotensive effects. Patients with cardiovascular disease including arrhythmias should also be treated with caution. Because Trifluoperazine oral solution may increase activity, care should be taken in patients with angina pectoris.
If an increase in pain is noted, the drug should be discontinued. Patients who have demonstrated bone marrow suppression or jaundice with a phenothiazine should not be re-exposed to Trifluoperazine oral solution (or any trifluoperazine) unless in the judgement of the physician the potential benefits of treatment outweigh the possible hazard.
In patients with Parkinson's disease, symptoms may be worsened, and the effects of levodopa reversed. Since phenothiazines may lower the convulsive threshold, patients with epilepsy should be treated with caution, and metrizamide avoided. Although Trifluoperazine oral solution has minimal anticholinergic activity, this should be borne in mind when treating patients with narrow angle glaucoma, myasthenia gravis or prostatic hypertrophy. Nausea and vomiting as a sign of organic disease may be masked by the anti-emetic action of Trifluoperazine oral solution.
An approximately 3-fold increased risk of cerebrovascular adverse events have been seen in randomised placebo controlled clinical trials in the dementia population with some atypical antipsychotics. The mechanism for this increased risk is not known. Trifluoperazine oral solution should be used with caution in patients with risk factors for stroke.
Caution should be used in patients with cardiovascular disease or family history of QT prolongation. Concomitant use of neuroleptics should be avoided.
Cases of venous thromboembolism (VTE) have been reported with antipsychotic drugs. Since patients treated with antipsychotics often present with acquired risk factors for VTE, all possible risk factors for VTE should be identified before and during treatment with Trifluoperazine oral solution and preventive measures undertaken.
Acute withdrawal symptoms, including nausea, vomiting, sweating, and insomnia have been described after abrupt cessation of antipsychotic drugs.
Recurrence of psychotic symptoms may also occur, and the emergence of involuntary movement disorders (such as akathisia, dystonia and dyskinesia) has been reported.
Therefore, gradual withdrawal is advisable.
Phenothiazines should be used with care in extremes of temperature since they may affect body temperature control.
Increased Mortality in Elderly people with Dementia
Data from two large observational studies showed that elderly people with dementia who are treated with antipsychotics are at a small increased risk of death compared with those who are not treated. There are insufficient data to give a firm estimate of the precise magnitude of the risk and the cause of the increased risk is not known.
Trifluoperazine oral solution is not licensed for the treatment of dementia-related behavioural disturbances.
Trifluoperazine 5mg/5ml Oral Solution contains sodium, ethanol, sodium benzoate, propylene glycol and benzyl alcohol.
This medicine contains less than 1 mmol sodium (23 mg) per ml, that is to say essentially 'sodium-free'.
This medicinal product contains small amounts of ethanol (alcohol), less than 100 mg per 25 ml.
This medicine contains 1 mg sodium benzoate in each ml.
This medicine contains 100.95 mg propylene glycol in each ml.
If your child is less than 5 years old, talk to your doctor or pharmacist before giving them this medicine, in particular if they use other medicines that contain propylene glycol or alcohol.
If you are pregnant or breast‑feeding, do not take this medicine unless recommended by your doctor. Your doctor may carry out extra checks while you are taking this medicine.
If you suffer from a liver or kidney disease, do not take this medicine unless recommended by your doctor. Your doctor may carry out extra checks while you are taking this medicine.
This medicine contains 0.0257 mg benzyl alcohol in each ml. Benzyl alcohol may cause allergic reactions.
Ask your doctor or pharmacist for advice if you are pregnant or breast‑feeding or if you have a liver or kidney disease. This is because large amounts of benzyl alcohol can build-up in your body and may cause side effects (called “metabolic acidosis”).
Potentiation may occur if antipsychotic drugs are combined with CNS depressants such as alcohol, hypnotics, anaesthetics and strong analgesics, or with antihypertensives or other drugs with hypotensive activity, anticholinergics or antidepressants. Phenothiazines may antagonise the action of guanethidine and levodopa. Trifluoperazine may aggravate Parkinsonism and antagonise the action of levodopa. They may lower the convulsive threshold. Hence patients with epilepsy should be treated with caution.
Serum levels of phenothiazine can be reduced to non-therapeutic concentrations by concurrent administration of lithium. Dosage increases may be needed.
Desferrioxamine should not be used in combination with Trifluoperazine oral solution, since prolonged unconsciousness has occurred after combination with the related prochlorperazine.
Trifluoperazine may diminish the effect of oral anticoagulants.
Severe extrapyramidal side-effects or neurotoxicity have been observed in patients concurrently treated with lithium and trifluoperazine. Sleep walking has been described in some patients taking phenothiazines and lithium.
Antacids can reduce the absorption of phenothiazines.
Patients on long-term phenothiazine therapy require regular and careful surveillance with particular attention to tardive dyskinesia and possible eye changes, blood dyscrasias, liver dysfunction and myocardial conduction defects, particularly if other concurrently administered drugs have potential effects in these systems.
Phenothiazines increase the risk of ventricular arrhythmias when given with drugs which prolong the Q-T interval; drugs causing electrolyte imbalances.
Pregnancy
Trifluoperazine has been available since 1958. There are some animal studies that indicate a teratogenic effect, but results are conflicting. There is no clinical evidence (including follow-up surveys in over 800 women who had taken low-dosage Trifluoperazine oral solution during pregnancy) to indicate that trifluoperazine has a teratogenic effect in man. Nevertheless, drug treatment should be avoided in pregnancy unless essential, especially during the first trimester.
Neonates exposed to antipsychotics (including Trifluoperazine) during the third trimester of pregnancy are at risk of adverse reactions including extrapyramidal and/or withdrawal symptoms that may vary in severity and duration following delivery. There have been reports of agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress, or feeding disorder. Consequently, newborns should be monitored carefully.
Breast-feeding
Trifluoperazine crosses the placenta and passes into the milk of lactating dogs; breast feeding should only be allowed at the discretion of the physician.
Fertility
There is currently no data available
Trifluoperazine oral solution may cause side effects including drowsiness, dizziness and visual disturbances which interfere with the ability to drive and operate machinery.
Do not drive or use machines when you first start to take this medicine until you are certain that you are not getting these side effects.
The following undesirable effects may occur with the use of Trifluoperazine in the following frequencies:
Rare (≥1/10,000 to <1/1,000);
Very rare (<1/10,000)
Not known (cannot be estimated from the available data).
The following effects have been reported and are listed below by body system:
System organ class
Frequency
Undesirable effects
Blood and lymphatic system disorders
Very rare
Blood dyscrasias1 such as agranulocytosis, pancytopenia, leucopenia and thrombocytopenia
Endocrine disorders
Not known
Hyperprolactinaemia2, galactorrhoea2, amenorrhoea2, gynaecomastia2
Metabolism and nutrition disorders
Not known
Anorexia, weight gain
Psychiatric disorders
Not known
Unpleasant symptoms3, Confusion,
Nervous system disorders
Rare
Extrapyramidal symptoms4, Neuroleptic malignant syndrome5,
Not known
Tardive dyskinesia6, drowsiness, dizziness, transient restlessness, insomnia,
Eye disorders
Very rare
Retinopathy, lenticular opacities
Not known
Blurred vision
Cardiac disorders
Rare
Serious arrhythmias, sudden unexplained death, cardiac arrest Torsades de pointes
Very rare
Tachycardia
Vascular disorders
Not known
Mild postural hypotension, venous thromboembolism, pulmonary embolism, deep vein thrombosis
Gastrointestinal disorders
Very rare
Constipation
Not known
Dry mouth
Hepatobiliary disorders
Very rare
Cholestatic jaundice
Skin and subcutaneous tissue disorders
Very rare
Skin pigmentation,
Not known
Photosensitivity reactions
Musculoskeletal and connective tissue disorders
Not known
Muscular weakness
Renal and urinary disorders
Very rare
Urinary hesitancy and retention
Pregnancy, puerperium and perinatal conditions
Not known
Drug withdrawal syndrome neonatal
General disorders and administration site conditions
Very rare
Hyperpyrexia
Not known
Lassitude, oedema, Withdrawal reactions
Investigations
Rare
ECG changes with prolongation of the QT interval and T-wave changes
Adverse reactions tend to be dose related and to disappear.
1Signs of persistent infection should be investigated.
2Hyperprolactinaemia may occur at higher dosages with associated effects such as galactorrhoea, amenorrhoea or gynaecomastia; certain hormone-dependent breast neoplasms may be affected.
3In some patients, especially non psychotic patients, trifluoperazine oral solution even at low dosage may cause unpleasant symptoms of being dulled or, paradoxically, of being agitated.
4Extrapyramidal symptoms are rare at daily oral dosages of 6 mg or less; they are considerably more common at higher dosage levels. These symptoms include parkinsonism; akathisia, with motor restlessness and difficulty in sitting still; and acute dystonia or dyskinesia, which may occur early in treatment and may present with torticollis, facial grimacing, trismus, tongue protrusion and abnormal eye movements including oculogyric crises. These effects are likely to be particularly severe in children. Such reactions may often be controlled by reducing the dosage or by stopping medication. In more severe dystonic reactions, an anticholinergic antiparkinsonism drug should be given.
5The neuroleptic malignant syndrome is a rare but occasionally fatal complication of treatment with various neuroleptic drugs, and is characterised by hyperpyrexia, muscle rigidity, altered consciousness and autonomic instability. Intensive symptomatic treatment, following discontinuation of Trifluoperazine oral solution should include cooling. Intravenous dantrolene has been suggested for muscle rigidity.
6Tardive dyskinesia of the facial muscles, sometimes with involuntary movements of the extremities, has occurred in some patients on long-term high dosage and, more rarely, low dosage phenothiazine therapy, including Trifluoperazine oral solution.
Symptoms may appear for the first time either during or after a course of treatment; they may become worse when treatment is stopped. The symptoms may persist for many months or even years, and while they gradually disappear in some patients, they appear to be permanent in others. Patients have most commonly been elderly, female, or with organic brain damage. Particular caution should be observed in treating such patients. Periodic gradual reduction of dosage to reveal persisting dyskinesia has been suggested, so that treatment may be stopped if necessary. Anticholinergic antiparkinsonism agents may aggravate the condition. Since the occurrence of tardive dyskinesia may be related to length of treatment and total cumulative dosage, Trifluoperazine oral solution should be given for as short a time and at as low a dosage as possible.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via Yellow Card Scheme
Website: www.mhra.gov.uk/yellowcard or search for MHRA yellow card in the Google play or Apple App Store .
Symptoms
Signs and symptoms will be predominantly extrapyramidal; hypotension may occur.
Management
Treatment consists of gastric lavage together with supportive and symptomatic measures. Do not induce vomiting. Extrapyramidal symptoms may be treated with an anticholinergic antiparkinsonism drug. Treat hypotension with fluid replacement; if severe or persistent, noradrenaline may be considered. Adrenaline is contraindicated.
Ask anything about Trifluoperazine 5 mg/5 ml Oral Solution. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.
Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.
We use essential cookies to make the site work. We would also like to set optional cookies to understand how the site is used, so we can improve it. We will not set optional cookies unless you accept. See our cookie policy and privacy policy.